AMSBIO has announced Solu BL21TM Competent E. coli, a significantly improved BL21 host strain for soluble mammalian protein expression. Using a directed evolution approach, a mutant strain of BL21(DE3) E. coli has been developed that can produce soluble protein in the majority of cases where expression in the parent BL21(DE3) yielded no detectable soluble product.
With Solu BL21TM a major obstacle to effective protein expression in E. coli has been overcome for many mammalian proteins. This significant improvement should enable scientists to make progress in a wide range of applications quicker and far less expensively than in the past.
Use of the Solu BL21TM Competent E. coli follows a simple and straightforward protocol, the product is compatible with all T7 promoter-based expression vectors.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized as a leading international provider of unique & innovative products & custom services for life sciences research. The AMSBIO range includes over 23,000 polyclonal & monoclonal antibodies, peptides, recombinant proteins, extracellular matrix, molecular detection reagents, & tissue DNA, RNA, protein & microarray products. Key research areas include: apoptosis, cell invasion & migration, cell signalling, DNA damage, electrophoresis, glycobiology, post translational modification and stem cell biology.
AMSBIO has announced Solu BL21TM Competent E. coli, a significantly improved BL21 host strain for soluble mammalian protein expression. Using a directed evolution approach, a mutant strain of BL21(DE3) E. coli has been developed that can produce soluble protein in the majority of cases where expression in the parent BL21(DE3) yielded no detectable soluble product.